New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases

Matteo Ferrando, Diego Bagnasco, Giovanni Passalacqua, Francesca Puggioni, Gilda Varricchi, Giorgio W. Canonica, Giorgio W. Canonica

Research output: Contribution to journalReview article

Abstract

© 2017 Bentham Science Publishers. Background: The indications for Allergen immunotherapy (AIT) in patients suffering from House Dust Mite (HDM)-related allergic diseases are presently based on incomplete data. This is essentially based on the fact that HDM allergy is difficult to evaluate in clinical trials, due to the largely variable allergen exposure and symptoms, and to the long periods of observation needed to assess the effects. In addition, at variance with pollen allergy, in HDM allergy asthma is more prevalent. However, several AIT products have been approved for HDM-induced allergic rhinitis, according to their ascertained clinical efficacy, tolerability and safety profile, particularly in the sublingual form (SLIT). Objective: We reviewed herein the available data on AIT in patients with HDM-induced allergic diseases, with a particular attention to the new product MK-8237 HDM-SLIT tablets, concerning its efficacy and safety profile. Method: In the recent years, several randomized placebo-controlled clinical trials have been performed in Europe, North America and Japan to evaluate the efficacy of HDM-sublingual tablets in patients with HDM-induced allergic asthma and allergic rhinitis, mainly assessing the reduction of symptoms, exacerbations and corticosteroid intake. Results: The results of the published clinical trials were encouraging and led to the approval and commercialization of MK-8237 HDM-SLIT tablet. Conclusion: The favorable efficacy and safety profile of MK-8237 HDM-SLIT tablets provided a consolidated therapeutic option for patients with HDM-induced allergic rhinitis and asthma.
Original languageEnglish
Pages (from-to)378-383
Number of pages6
JournalCurrent Pharmaceutical Biotechnology
Volume18
Issue number5
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Sublingual Immunotherapy
Pyroglyphidae
Immunologic Desensitization
Tablets
Asthma
Safety
Hypersensitivity
Clinical Trials
Seasonal Allergic Rhinitis
North America
Allergens
Japan
Adrenal Cortex Hormones

Keywords

  • Allergy
  • Asthma
  • Houde dust mite
  • MK-8237
  • Rhinitis
  • SLIT
  • Sublingual immunotherapy
  • Tablets

Cite this

New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases. / Ferrando, Matteo; Bagnasco, Diego; Passalacqua, Giovanni; Puggioni, Francesca; Varricchi, Gilda; Canonica, Giorgio W.; Canonica, Giorgio W.

In: Current Pharmaceutical Biotechnology, Vol. 18, No. 5, 01.04.2017, p. 378-383.

Research output: Contribution to journalReview article

@article{191214c90edf4d338c408b8e0001121e,
title = "New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases",
abstract = "{\circledC} 2017 Bentham Science Publishers. Background: The indications for Allergen immunotherapy (AIT) in patients suffering from House Dust Mite (HDM)-related allergic diseases are presently based on incomplete data. This is essentially based on the fact that HDM allergy is difficult to evaluate in clinical trials, due to the largely variable allergen exposure and symptoms, and to the long periods of observation needed to assess the effects. In addition, at variance with pollen allergy, in HDM allergy asthma is more prevalent. However, several AIT products have been approved for HDM-induced allergic rhinitis, according to their ascertained clinical efficacy, tolerability and safety profile, particularly in the sublingual form (SLIT). Objective: We reviewed herein the available data on AIT in patients with HDM-induced allergic diseases, with a particular attention to the new product MK-8237 HDM-SLIT tablets, concerning its efficacy and safety profile. Method: In the recent years, several randomized placebo-controlled clinical trials have been performed in Europe, North America and Japan to evaluate the efficacy of HDM-sublingual tablets in patients with HDM-induced allergic asthma and allergic rhinitis, mainly assessing the reduction of symptoms, exacerbations and corticosteroid intake. Results: The results of the published clinical trials were encouraging and led to the approval and commercialization of MK-8237 HDM-SLIT tablet. Conclusion: The favorable efficacy and safety profile of MK-8237 HDM-SLIT tablets provided a consolidated therapeutic option for patients with HDM-induced allergic rhinitis and asthma.",
keywords = "Allergy, Asthma, Houde dust mite, MK-8237, Rhinitis, SLIT, Sublingual immunotherapy, Tablets",
author = "Matteo Ferrando and Diego Bagnasco and Giovanni Passalacqua and Francesca Puggioni and Gilda Varricchi and Canonica, {Giorgio W.} and Canonica, {Giorgio W.}",
year = "2017",
month = "4",
day = "1",
doi = "10.2174/1389201018666170417103316",
language = "English",
volume = "18",
pages = "378--383",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases

AU - Ferrando, Matteo

AU - Bagnasco, Diego

AU - Passalacqua, Giovanni

AU - Puggioni, Francesca

AU - Varricchi, Gilda

AU - Canonica, Giorgio W.

AU - Canonica, Giorgio W.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - © 2017 Bentham Science Publishers. Background: The indications for Allergen immunotherapy (AIT) in patients suffering from House Dust Mite (HDM)-related allergic diseases are presently based on incomplete data. This is essentially based on the fact that HDM allergy is difficult to evaluate in clinical trials, due to the largely variable allergen exposure and symptoms, and to the long periods of observation needed to assess the effects. In addition, at variance with pollen allergy, in HDM allergy asthma is more prevalent. However, several AIT products have been approved for HDM-induced allergic rhinitis, according to their ascertained clinical efficacy, tolerability and safety profile, particularly in the sublingual form (SLIT). Objective: We reviewed herein the available data on AIT in patients with HDM-induced allergic diseases, with a particular attention to the new product MK-8237 HDM-SLIT tablets, concerning its efficacy and safety profile. Method: In the recent years, several randomized placebo-controlled clinical trials have been performed in Europe, North America and Japan to evaluate the efficacy of HDM-sublingual tablets in patients with HDM-induced allergic asthma and allergic rhinitis, mainly assessing the reduction of symptoms, exacerbations and corticosteroid intake. Results: The results of the published clinical trials were encouraging and led to the approval and commercialization of MK-8237 HDM-SLIT tablet. Conclusion: The favorable efficacy and safety profile of MK-8237 HDM-SLIT tablets provided a consolidated therapeutic option for patients with HDM-induced allergic rhinitis and asthma.

AB - © 2017 Bentham Science Publishers. Background: The indications for Allergen immunotherapy (AIT) in patients suffering from House Dust Mite (HDM)-related allergic diseases are presently based on incomplete data. This is essentially based on the fact that HDM allergy is difficult to evaluate in clinical trials, due to the largely variable allergen exposure and symptoms, and to the long periods of observation needed to assess the effects. In addition, at variance with pollen allergy, in HDM allergy asthma is more prevalent. However, several AIT products have been approved for HDM-induced allergic rhinitis, according to their ascertained clinical efficacy, tolerability and safety profile, particularly in the sublingual form (SLIT). Objective: We reviewed herein the available data on AIT in patients with HDM-induced allergic diseases, with a particular attention to the new product MK-8237 HDM-SLIT tablets, concerning its efficacy and safety profile. Method: In the recent years, several randomized placebo-controlled clinical trials have been performed in Europe, North America and Japan to evaluate the efficacy of HDM-sublingual tablets in patients with HDM-induced allergic asthma and allergic rhinitis, mainly assessing the reduction of symptoms, exacerbations and corticosteroid intake. Results: The results of the published clinical trials were encouraging and led to the approval and commercialization of MK-8237 HDM-SLIT tablet. Conclusion: The favorable efficacy and safety profile of MK-8237 HDM-SLIT tablets provided a consolidated therapeutic option for patients with HDM-induced allergic rhinitis and asthma.

KW - Allergy

KW - Asthma

KW - Houde dust mite

KW - MK-8237

KW - Rhinitis

KW - SLIT

KW - Sublingual immunotherapy

KW - Tablets

UR - http://www.scopus.com/inward/record.url?scp=85027272030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027272030&partnerID=8YFLogxK

U2 - 10.2174/1389201018666170417103316

DO - 10.2174/1389201018666170417103316

M3 - Review article

AN - SCOPUS:85027272030

VL - 18

SP - 378

EP - 383

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 5

ER -